Where does Neuboron Therapy System Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Neuboron Therapy System Ltd. ranks #17,027 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Neuboron Therapy System Ltd. hold?

Neuboron Therapy System Ltd. holds 17 US utility patents granted between 2023 and 2025, spanning 12 technology areas.

What is Neuboron Therapy System Ltd.'s Innovation Score?

Neuboron Therapy System Ltd. has an Innovation Score of 52.6 out of 100 (top 10% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Neuboron Therapy System Ltd. focus on?

Neuboron Therapy System Ltd.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 17 patents, ranking #211 of 1,943 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Neuboron Therapy System Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Neuboron Therapy System Ltd..

What does claim depth mean for Neuboron Therapy System Ltd.'s patents?

Neuboron Therapy System Ltd.'s patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Neuboron Therapy System Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Neuboron Therapy System Ltd.

USPTO PatentsView assignee record - 17 granted patents across 12 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neuboron ranks #17,027 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 12 technology areas.

#17,027
of 49,997 US assignees by volume: Top 10%
by Innovation Score (52.6/100): 17.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R17027 · Foreign Corporation #17,027 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 17 grants
MID-PACK #17,027/49,997
PHOTO-FINISH Nami MOS
CPC-FOCUS A61N · 12 areas
INNOV-PAR 52.6/100
CLAIMS-RICH 17.2 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Nami MOS Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neuboron’s 52.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (19%) Velocity 20.0 pts (38%) Breadth 12.2 pts (23%) Claim depth 10.3 pts (20%)

Qualcomm Incorporated · highest

85
Neuboron Therapy… · this assignee

53
3D Lighting… · lowest

7

What this shows Neuboron's Innovation Score is 52.6/100 (top 10% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Neuboron?

Each dot is one of Neuboron’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neuboron’s own 17.2 claims/patent is ABOVE the 13.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neuboron vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neuboron's grants concentrate

Neuboron Therapy System Ltd. is a focused PatentsView assignee: 12 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2024 (5 grants) versus a trough of 1 in 2023. By volume, Neuboron sits between Nami MOS Co., Ltd. and NEW Power Plasma Co., Ltd..

Neuboron's three-year grant acceleration

Neuboron Therapy System Ltd. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nami MOS

17
Nano Intelligent…

17
National Associat…

17
Neograf Solutions

17
Neuracle Science

17
Neuro Kinetics

17
Neuspera Medical

17
NEW Power Plasma

17
Neuboron Therapy… ◀

17

What this shows Neuboron holds 17 patents at rank #17,014, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Neuboron

By rank, the assignees closest to #17,014 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Neuboron's primary technology class.

Neuboron's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

53 Top 10% higher than 90% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Neuboron Therapy System Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	1	5.9%
2024	5	29.4%
2025partial year	11	64.7%

Which technologies does Neuboron Therapy System Ltd. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 17

G21K - Techniques FOR Handling Particles OR Ionising Radiation NOT Otherwise Provided FOR; Irradiation DEVICES; Gamma RAY OR X-ray Microscopes 7

H05H - Plasma Technique ; Production OF Accelerated Electrically-charged Particles OR OF NEUTRONS; Production OR Acceleration OF Neutral Molecular OR Atomic Beams 5

Y02E - Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution 4

G21F - Protection Against X-radiation, Gamma Radiation, Corpuscular Radiation OR Particle BOMBARDMENT; Treating Radioactively Contaminated MATERIAL; Decontamination Arrangements Therefor 4

G21G - Conversion OF Chemical ELEMENTS; Radioactive Sources 4

A61B - DIAGNOSIS; SURGERY; Identification 3

C23C - Coating Metallic MATERIAL; Coating Material With Metallic MATERIAL; Surface Treatment OF Metallic Material BY Diffusion Into THE Surface, BY Chemical Conversion OR SUBSTITUTION; Coating BY Vacuum Evaporation, BY Sputtering, BY ION Implantation OR BY Chemical Vapour Deposition, IN General 2

A61G - Transport, Personal Conveyances, OR Accommodation Specially Adapted FOR Patients OR Disabled Persons ; Operating Tables OR CHAIRS; Chairs FOR DENTISTRY; Funeral Devices 1

E04C - Structural ELEMENTS; Building Materials 1

E04B - General Building CONSTRUCTIONS; Walls, e.g. PARTITIONS; ROOFS; FLOORS; CEILINGS; Insulation OR Other Protection OF Buildings 1

G01T - Measurement OF Nuclear OR X-radiation 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Neuboron Therapy System Ltd.'s patent record in context - here's where to go next.

Neuboron Therapy System Ltd.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #17,027 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Neuboron Therapy System Ltd. against Nami MOS Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 52.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.